Trials / Completed
CompletedNCT01926899
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- All
- Age
- 1 Year – 21 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with calcineurin inhibitor and methotrexate as acute graft versus host disease (aGVHD) prophylaxis in pediatric patients undergoing allogeniec hematopoietic stem cell transplant (alloHSCT)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib administration |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2018-02-01
- Completion
- 2018-03-15
- First posted
- 2013-08-21
- Last updated
- 2018-03-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01926899. Inclusion in this directory is not an endorsement.